{
  "profiles": [
    {
      "pi_name": "Ka Yu Tse, MBBS, MMedSc, PhD, FRCOG",
      "institution": "The University of Hong Kong",
      "nct_id": "NCT07022535",
      "trial_details": {
        "title": "Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer",
        "phase": [
          "PHASE2"
        ],
        "interventions": [
          "KELIM",
          "Carboplatin plus Paclitaxel",
          "Interval debulking surgery"
        ]
      },
      "publications": [
        "40908776",
        "40611334",
        "39776385"
      ],
      "kelim_fit": {
        "fit_reasons": [
          "Has relevant publications"
        ],
        "fit_score": 1
      },
      "personalized_email": "Subject: KELIM Biomarker Validation - Collaboration Opportunity\n\nDear Dr. Ka Yu Tse,\n\nI hope this email finds you well. I am reaching out regarding a research collaboration opportunity for validating the KELIM (CA-125 elimination rate) biomarker for predicting platinum resistance in ovarian cancer.\n\n**Why Your Trial is Ideal:**\nYour trial \"Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer\" (NCTNCT07022535) Has relevant publications, making it an ideal candidate for KELIM validation.\n\n**What We Need:**\n- Serial CA-125 measurements (\u22652 per patient)\n- Platinum-free interval (PFI) outcomes\n- 50-100 patients minimum\n\n**Benefits:**\n- Co-authorship on validation publication\n- Access to validated biomarker for your research\n- Contribution to advancing ovarian cancer treatment\n\nWe would be happy to discuss data sharing agreements, IRB considerations, and co-authorship details.\n\nThank you for your consideration.\n\nBest regards,\n[Your Name]\n"
    },
    {
      "pi_name": "Clinical Trial Management",
      "institution": "Regeneron Pharmaceuticals",
      "nct_id": "NCT04590326",
      "trial_details": {
        "title": "A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab",
        "phase": [
          "PHASE1",
          "PHASE2"
        ],
        "interventions": [
          "REGN5668",
          "Cemiplimab",
          "Ubamatamab",
          "Sarilumab",
          "Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]"
        ]
      },
      "publications": [],
      "kelim_fit": {
        "fit_reasons": [],
        "fit_score": 0
      },
      "personalized_email": "Subject: KELIM Biomarker Validation - Collaboration Opportunity\n\nDear Dr. Clinical,\n\nI hope this email finds you well. I am reaching out regarding a research collaboration opportunity for validating the KELIM (CA-125 elimination rate) biomarker for predicting platinum resistance in ovarian cancer.\n\n**Why Your Trial is Ideal:**\nYour trial \"A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab\" (NCTNCT04590326) involves CA-125 monitoring, making it an ideal candidate for KELIM validation.\n\n**What We Need:**\n- Serial CA-125 measurements (\u22652 per patient)\n- Platinum-free interval (PFI) outcomes\n- 50-100 patients minimum\n\n**Benefits:**\n- Co-authorship on validation publication\n- Access to validated biomarker for your research\n- Contribution to advancing ovarian cancer treatment\n\nWe would be happy to discuss data sharing agreements, IRB considerations, and co-authorship details.\n\nThank you for your consideration.\n\nBest regards,\n[Your Name]\n"
    },
    {
      "pi_name": "David Alberts, MD",
      "institution": "University of Arizona",
      "nct_id": "NCT00442598",
      "trial_details": {
        "title": "Safety and Efficacy Study of Glufosfamide in Ovarian Cancer",
        "phase": [
          "PHASE2"
        ],
        "interventions": [
          "Glufosfamide"
        ]
      },
      "publications": [
        "38640774",
        "36608382",
        "34216135"
      ],
      "kelim_fit": {
        "fit_reasons": [
          "Has relevant publications"
        ],
        "fit_score": 1
      },
      "personalized_email": "Subject: KELIM Biomarker Validation - Collaboration Opportunity\n\nDear Dr. David Alberts,\n\nI hope this email finds you well. I am reaching out regarding a research collaboration opportunity for validating the KELIM (CA-125 elimination rate) biomarker for predicting platinum resistance in ovarian cancer.\n\n**Why Your Trial is Ideal:**\nYour trial \"Safety and Efficacy Study of Glufosfamide in Ovarian Cancer\" (NCTNCT00442598) Has relevant publications, making it an ideal candidate for KELIM validation.\n\n**What We Need:**\n- Serial CA-125 measurements (\u22652 per patient)\n- Platinum-free interval (PFI) outcomes\n- 50-100 patients minimum\n\n**Benefits:**\n- Co-authorship on validation publication\n- Access to validated biomarker for your research\n- Contribution to advancing ovarian cancer treatment\n\nWe would be happy to discuss data sharing agreements, IRB considerations, and co-authorship details.\n\nThank you for your consideration.\n\nBest regards,\n[Your Name]\n"
    },
    {
      "pi_name": "Dae-Yeon Kim",
      "institution": "Asam Medical Center",
      "nct_id": "NCT07295132",
      "trial_details": {
        "title": "RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse)",
        "phase": [
          "PHASE2"
        ],
        "interventions": [
          "Secondary cytoreductive surgery",
          "Platinum Based Chemotherapy"
        ]
      },
      "publications": [
        "41311345",
        "40943311",
        "40842255"
      ],
      "kelim_fit": {
        "fit_reasons": [
          "Uses platinum therapy",
          "Has relevant publications"
        ],
        "fit_score": 2
      },
      "personalized_email": "Subject: KELIM Biomarker Validation - Collaboration Opportunity\n\nDear Dr. Dae-Yeon,\n\nI hope this email finds you well. I am reaching out regarding a research collaboration opportunity for validating the KELIM (CA-125 elimination rate) biomarker for predicting platinum resistance in ovarian cancer.\n\n**Why Your Trial is Ideal:**\nYour trial \"RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse)\" (NCTNCT07295132) Uses platinum therapy, Has relevant publications, making it an ideal candidate for KELIM validation.\n\n**What We Need:**\n- Serial CA-125 measurements (\u22652 per patient)\n- Platinum-free interval (PFI) outcomes\n- 50-100 patients minimum\n\n**Benefits:**\n- Co-authorship on validation publication\n- Access to validated biomarker for your research\n- Contribution to advancing ovarian cancer treatment\n\nWe would be happy to discuss data sharing agreements, IRB considerations, and co-authorship details.\n\nThank you for your consideration.\n\nBest regards,\n[Your Name]\n"
    },
    {
      "pi_name": "Laurent Brard, MD, PhD",
      "institution": "Southern Illinois University",
      "nct_id": "NCT02109367",
      "trial_details": {
        "title": "Diagnostic Utility of Culdocentesis in Patients With a Suspicious Adnexal Mass",
        "phase": [],
        "interventions": []
      },
      "publications": [
        "41041279",
        "38492533",
        "37153054"
      ],
      "kelim_fit": {
        "fit_reasons": [
          "Has relevant publications"
        ],
        "fit_score": 1
      },
      "personalized_email": "Subject: KELIM Biomarker Validation - Collaboration Opportunity\n\nDear Dr. Laurent Brard,\n\nI hope this email finds you well. I am reaching out regarding a research collaboration opportunity for validating the KELIM (CA-125 elimination rate) biomarker for predicting platinum resistance in ovarian cancer.\n\n**Why Your Trial is Ideal:**\nYour trial \"Diagnostic Utility of Culdocentesis in Patients With a Suspicious Adnexal Mass\" (NCTNCT02109367) Has relevant publications, making it an ideal candidate for KELIM validation.\n\n**What We Need:**\n- Serial CA-125 measurements (\u22652 per patient)\n- Platinum-free interval (PFI) outcomes\n- 50-100 patients minimum\n\n**Benefits:**\n- Co-authorship on validation publication\n- Access to validated biomarker for your research\n- Contribution to advancing ovarian cancer treatment\n\nWe would be happy to discuss data sharing agreements, IRB considerations, and co-authorship details.\n\nThank you for your consideration.\n\nBest regards,\n[Your Name]\n"
    },
    {
      "pi_name": "Thomas Woo, M.Sc.",
      "institution": "Quest PharmaTech Inc.",
      "nct_id": "NCT01616303",
      "trial_details": {
        "title": "A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer",
        "phase": [
          "PHASE2"
        ],
        "interventions": [
          "Carboplatin",
          "Paclitaxel",
          "oregovomab"
        ]
      },
      "publications": [
        "33477405",
        "24303006",
        "21658270"
      ],
      "kelim_fit": {
        "fit_reasons": [
          "Has relevant publications"
        ],
        "fit_score": 1
      },
      "personalized_email": "Subject: KELIM Biomarker Validation - Collaboration Opportunity\n\nDear Dr. Thomas Woo,\n\nI hope this email finds you well. I am reaching out regarding a research collaboration opportunity for validating the KELIM (CA-125 elimination rate) biomarker for predicting platinum resistance in ovarian cancer.\n\n**Why Your Trial is Ideal:**\nYour trial \"A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer\" (NCTNCT01616303) Has relevant publications, making it an ideal candidate for KELIM validation.\n\n**What We Need:**\n- Serial CA-125 measurements (\u22652 per patient)\n- Platinum-free interval (PFI) outcomes\n- 50-100 patients minimum\n\n**Benefits:**\n- Co-authorship on validation publication\n- Access to validated biomarker for your research\n- Contribution to advancing ovarian cancer treatment\n\nWe would be happy to discuss data sharing agreements, IRB considerations, and co-authorship details.\n\nThank you for your consideration.\n\nBest regards,\n[Your Name]\n"
    },
    {
      "pi_name": "Sudha Sundar",
      "institution": "University of Birmingham/Sandwell and West Birmingham NHS Trust",
      "nct_id": "NCT06129968",
      "trial_details": {
        "title": "Transforming Ovarian Cancer Diagnostic Pathways",
        "phase": [],
        "interventions": []
      },
      "publications": [
        "41321325",
        "41228382",
        "41194592"
      ],
      "kelim_fit": {
        "fit_reasons": [
          "Has relevant publications"
        ],
        "fit_score": 1
      },
      "personalized_email": "Subject: KELIM Biomarker Validation - Collaboration Opportunity\n\nDear Dr. Sudha,\n\nI hope this email finds you well. I am reaching out regarding a research collaboration opportunity for validating the KELIM (CA-125 elimination rate) biomarker for predicting platinum resistance in ovarian cancer.\n\n**Why Your Trial is Ideal:**\nYour trial \"Transforming Ovarian Cancer Diagnostic Pathways\" (NCTNCT06129968) Has relevant publications, making it an ideal candidate for KELIM validation.\n\n**What We Need:**\n- Serial CA-125 measurements (\u22652 per patient)\n- Platinum-free interval (PFI) outcomes\n- 50-100 patients minimum\n\n**Benefits:**\n- Co-authorship on validation publication\n- Access to validated biomarker for your research\n- Contribution to advancing ovarian cancer treatment\n\nWe would be happy to discuss data sharing agreements, IRB considerations, and co-authorship details.\n\nThank you for your consideration.\n\nBest regards,\n[Your Name]\n"
    },
    {
      "pi_name": "Elise C Kohn, M.D.",
      "institution": "National Cancer Institute (NCI)",
      "nct_id": "NCT00086567",
      "trial_details": {
        "title": "Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers",
        "phase": [],
        "interventions": []
      },
      "publications": [
        "40192715",
        "39496422",
        "39361946"
      ],
      "kelim_fit": {
        "fit_reasons": [
          "Has relevant publications"
        ],
        "fit_score": 1
      },
      "personalized_email": "Subject: KELIM Biomarker Validation - Collaboration Opportunity\n\nDear Dr. Elise C Kohn,\n\nI hope this email finds you well. I am reaching out regarding a research collaboration opportunity for validating the KELIM (CA-125 elimination rate) biomarker for predicting platinum resistance in ovarian cancer.\n\n**Why Your Trial is Ideal:**\nYour trial \"Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers\" (NCTNCT00086567) Has relevant publications, making it an ideal candidate for KELIM validation.\n\n**What We Need:**\n- Serial CA-125 measurements (\u22652 per patient)\n- Platinum-free interval (PFI) outcomes\n- 50-100 patients minimum\n\n**Benefits:**\n- Co-authorship on validation publication\n- Access to validated biomarker for your research\n- Contribution to advancing ovarian cancer treatment\n\nWe would be happy to discuss data sharing agreements, IRB considerations, and co-authorship details.\n\nThank you for your consideration.\n\nBest regards,\n[Your Name]\n"
    },
    {
      "pi_name": "Guillaume DUCARME, PH",
      "institution": "CHD Vend\u00e9e",
      "nct_id": "NCT02326064",
      "trial_details": {},
      "publications": [
        "31699959",
        "30917847",
        "22657746"
      ],
      "kelim_fit": {
        "fit_reasons": [
          "Has relevant publications"
        ],
        "fit_score": 1
      },
      "personalized_email": "Subject: KELIM Biomarker Validation - Collaboration Opportunity\n\nDear Dr. Guillaume DUCARME,\n\nI hope this email finds you well. I am reaching out regarding a research collaboration opportunity for validating the KELIM (CA-125 elimination rate) biomarker for predicting platinum resistance in ovarian cancer.\n\n**Why Your Trial is Ideal:**\nYour trial \"N/A\" (NCTNCT02326064) Has relevant publications, making it an ideal candidate for KELIM validation.\n\n**What We Need:**\n- Serial CA-125 measurements (\u22652 per patient)\n- Platinum-free interval (PFI) outcomes\n- 50-100 patients minimum\n\n**Benefits:**\n- Co-authorship on validation publication\n- Access to validated biomarker for your research\n- Contribution to advancing ovarian cancer treatment\n\nWe would be happy to discuss data sharing agreements, IRB considerations, and co-authorship details.\n\nThank you for your consideration.\n\nBest regards,\n[Your Name]\n"
    },
    {
      "pi_name": "Lucy Gilbert, MD,MSc,FRCOG",
      "institution": "McGill University",
      "nct_id": "NCT02296307",
      "trial_details": {
        "title": "DOvEE - Diagnosing Ovarian & Endometrial Cancer Early",
        "phase": [],
        "interventions": [
          "Blood test: CA-125 biomarker",
          "Second Test: Transvaginal Ultrasound",
          "Follow-up phone call"
        ]
      },
      "publications": [
        "41079774",
        "40700855",
        "40568887"
      ],
      "kelim_fit": {
        "fit_reasons": [
          "Has relevant publications"
        ],
        "fit_score": 1
      },
      "personalized_email": "Subject: KELIM Biomarker Validation - Collaboration Opportunity\n\nDear Dr. Lucy Gilbert,\n\nI hope this email finds you well. I am reaching out regarding a research collaboration opportunity for validating the KELIM (CA-125 elimination rate) biomarker for predicting platinum resistance in ovarian cancer.\n\n**Why Your Trial is Ideal:**\nYour trial \"DOvEE - Diagnosing Ovarian & Endometrial Cancer Early\" (NCTNCT02296307) Has relevant publications, making it an ideal candidate for KELIM validation.\n\n**What We Need:**\n- Serial CA-125 measurements (\u22652 per patient)\n- Platinum-free interval (PFI) outcomes\n- 50-100 patients minimum\n\n**Benefits:**\n- Co-authorship on validation publication\n- Access to validated biomarker for your research\n- Contribution to advancing ovarian cancer treatment\n\nWe would be happy to discuss data sharing agreements, IRB considerations, and co-authorship details.\n\nThank you for your consideration.\n\nBest regards,\n[Your Name]\n"
    }
  ],
  "date": "2025-12-30T02:41:23.473474"
}